Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire

AIDS

Volumn 25, Issue 10, 2011, Pages 1259-1264

  Parsons, Matthew S ^a,b,c   Rouleau, Danielle ^d   Routy, Jean Pierre ^a,b,c   Leblanc, Roger ^a,e   Grant, Michael D ^f   Bernard, Nicole F ^a,b,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Clinique LORI   (Canada)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

1F7 idiotype; antibody selection; broadly neutralizing antibodies; HIV infection; repertoire freeze

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IDIOTYPIC ANTIBODY; IDIOTYPIC ANTIBODY 1F7; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN IDIOTYPE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SCREENING; PRIORITY JOURNAL; PROTEIN EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED;

ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN IDIOTYPES; MALE; MIDDLE AGED;

EID: 79958863431     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347f9fa     Document Type: Article

References (25)

1. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5-25. (Pubitemid 47000630)
2. Alter G, Moody MA. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 2010; 202 (Suppl 2):S315-S322.
3. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905. (Pubitemid 33034579)
4. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007; 81:4033-4043. (Pubitemid 46586898)
5. Walker LM, Phogat SK, Chan-Hui PY, WagnerD,Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
6. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861.
7. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
8. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84:1302-1313.
9. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189:2167-2173. (Pubitemid 38757187)
10. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007; 81:8793-8808. (Pubitemid 47242852)
11. Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 2005; 19:1957-1966. (Pubitemid 41669019)
12. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-870.
13. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010; 201:1045-1053.
14. KohlerH,MullerS,NaraPL.Deceptive imprintinginthe immune response against HIV-1. Immunol Today 1994; 15:475-478. (Pubitemid 24316013)
15. Muller S, Wang HT, Kaveri SV, Chattopadhyay S, Kohler H. Generation and specificity of monoclonal antiidiotypic antibodies against human HIV-specific antibodies. I. Cross-reacting idiotopes are expressed in subpopulations of HIV-infected individuals. J Immunol 1991; 147:933-941.
16. Wang H, Muller S, Zolla-Pazner S, Kohler H. Human monoclonal and polyclonal antihuman immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur J Immunol 1992; 22:1749-1755.
17. Muller S, Margolin DH, Min G. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus-and chimeric simian/human immunodeficiency virus-infected rhesus monkeys. Hybridoma 1997; 16:17-21. (Pubitemid 27148684)
18. Muller S, Margolin DH, Nara PL, Alvord WG, Kohler H. Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques. Proc Natl Acad Sci USA 1998; 95: 276-281. (Pubitemid 28103944)
19. Muller S, Margolin DH, Min G, Lou D, Nara P, Axthelm MK, et al. Stimulation of antiviral antibody response in SHIV-IIIB-infected macaques. Scand J Immunol 2001; 54:383-395. (Pubitemid 32955660)
20. Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, et al. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J Immunol 2003; 171:477-488. (Pubitemid 36745323)
21. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48. (Pubitemid 28414995)
22. Davtyan TK, Hovsepyan MP, Mkhitaryan LM, Hakobyan GS, Brazil A, Barrett L, et al. The 1F7 idiotype is selectively expressed on CD5R B cells and elevated in chronic hepatitis C virus infection. Immunol Cell Biol 2009; 87:457-463.
23. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 2011; 17:108-116.
24. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
25. Veljkovic V, Metlas R, Kohler H, Urnovitz HB, Prljic J, Veljkovic N, et al. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. Vaccine 2001; 19:1855-1862. (Pubitemid 32178332)